Skip to content

    Breast Cancer Health Center

    Font Size
    A
    A
    A

    Femara May Be Better Than Tamoxifen

    Side Effects of Breast Cancer Drugs May Determine Choice
    By
    WebMD Health News
    Reviewed by Louise Chang, MD

    Dec. 28, 2005 - It's official: Femara beats tamoxifen in preventing breast-cancer recurrence.

    A large 27-nation clinical trial shows that postmenopausal women with estrogen-receptor-positive breast cancer are less likely to get new breast cancers -- especially cancers in distant parts of the body -- if they take Femara than if they take tamoxifen.

    "Particularly notable was our finding of a significant [27%] reduction in the risk of distant recurrence with Femara as compared with tamoxifen," write Beat Thürlimann, MD, and colleagues. Thürlimann, a senior lecturer at the University of Basel, Switzerland, owns stock in Novartis, which makes Femara. Novartis is a WebMD sponsor.

    We've heard the news before: first from Novartis, which makes the drug, and then at a meeting of cancer specialists. Now the report on the Breast International Group (BIG) 1-98 study appears in the Dec. 29 issue of The New England Journal of Medicine.

    It's not that tamoxifen didn't work. Cancer-free, five-year survival was estimated at 84% for women taking tamoxifen -- only 2.6% lower than for Femara. Yet Femara had a distinct benefit, with a 27% lower risk of metastatic (distant-spreading) cancer.

    Tamoxifen Still Has Large Role

    Femara is the most potent member of a new class of drugs called aromatase inhibitors. These drugs almost totally shut down the body's ability to make estrogen. Estrogen-receptor-positive tumors grow in the presence of estrogen. Tamoxifen also blocks estrogen's effects, but not in the same way as Femara and its sister drugs Arimidex and Aromasin.

    Other large clinical trials show that Femara and other aromatase inhibitors fight breast cancer better than tamoxifen, notes an NEJM editorial by Sandra M. Swain, MD, of the U.S. National Cancer Institute.

    "It is clear ... that these trials, with close to 30,000 participants, consistently demonstrate that treatment with an aromatase inhibitor alone or after tamoxifen treatment is beneficial," Swain writes.

    Choosing a Treatment Plan

    Swain says many questions remain:

    • How long should treatment last?
    • Should patients take tamoxifen before an aromatase inhibitor, or after?
    • Which is best: Femara, Arimidex, or Aromasin?
    • Is taking one drug and then another beneficial?
    • Do women whose ovaries have been removed benefit from aromatase inhibitors?

    Today on WebMD

    Breast Cancer Overview
    From mammograms to living after treatment.
    Dealing with breast cancer
    Get answers to your questions.
     
    woman having mammogram
    The 3 latest tips to know.
    woman undergoing breast cancer test
    Most abnormalities aren’t breast cancer.
     
    Resolved To Quit Smoking
    VIDEO
    Breast Cancer Treatments Improving
    Article
     
    Woman getting mammogram
    Article
    Screening Tests for Women
    Article
     
    serious woman
    Article
    Pink badge on woman chest to support breat cancer
    QUIZ
     
    what is your cancer risk
    Article
    breast cancer survivors
    Article